| Literature DB >> 22984450 |
Yi-Chun Chen1, Yi-Wen Chien, Pei-Jen Chang, Wu-Shiun Hsieh, Pau-Chung Chen.
Abstract
OBJECTIVES: The objective of this study is to provide details on probiotic supplement use among young children in Taiwan. PARTICIPANTS AND METHODS: This study is based on the Taiwan Birth Cohort Study database. We used questionnaires to collect information on probiotic supplement use among young children from birth to 18 months of age, while also considering their demographic characteristics and other covariates. Low-birth-weight infants, preterm infants, those with birth defects, and those with caregivers who returned incomplete questionnaires were excluded. The final valid sample comprised 16,991 cases.Entities:
Mesh:
Year: 2012 PMID: 22984450 PMCID: PMC3440429 DOI: 10.1371/journal.pone.0043885
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Probiotic supplement use according to different characteristic variables.
| nonuser | 0–6 mo user | 7–18 mo user | 0–18 mo user |
| |
|
| 8,582(50.5) | 1,616(9.5) | 5,720(33.7) | 1,073(6.3) | |
|
| |||||
|
| <0.001 | ||||
|
| 4,347 (52.8) | 811 (9.9) | 2,592 (31.5) | 477 (5.8) | |
|
| 4,235 (48.3) | 805 (9.2) | 3128 (35.7) | 596 (6.8) | |
|
| <0.001 | ||||
|
| 5,024 (54.8) | 927 (10.1) | 2,697 (29.4) | 524 (5.7) | |
|
| 3,558 (45.5) | 689 (8.8) | 3,023 (38.7) | 549 (7.0) | |
|
| <0.001 | ||||
|
| 1,503 (67.5) | 282 (12.7) | 366 (16.4) | 77 (3.5) | |
|
| 7,079 (48.0) | 1,334 (9.0) | 5,354 (36.3) | 996 (6.7) | |
|
| <0.001 | ||||
|
| 3,875 (55.3) | 767 (10.9) | 1,971 (28.1) | 398 (5.7) | |
|
| 2,147 (48.2) | 399 (9.0) | 1,614 (36.2) | 294 (6.6) | |
|
| 1,676 (45.9) | 297 (8.1) | 1,408 (38.6) | 269 (7.4) | |
|
| 884 (47.1) | 153 (8.2) | 727 (38.8) | 112 (6.0) | |
|
| <0.001 | ||||
|
| 2,262 (53.4) | 383 (9.1) | 1,343 (31.7) | 244 (5.8) | |
|
| 2,437 (51.4) | 520 (11.0) | 1,462 (30.8) | 324 (6.8) | |
|
| 3,883 (48.4) | 713 (8.9) | 2,915 (36.4) | 505 (6.3) | |
|
| |||||
|
| 0.011 | ||||
|
| 5,199 (51.4) | 972 (9.6) | 3,309 (32.7) | 631 (6.2) | |
|
| 3,383 (49.2) | 644 (9.4) | 2,411 (35.0) | 442 (6.4) | |
|
| <0.001 | ||||
|
| 5,857 (52.1) | 1,081 (9.6) | 3,620 (32.2) | 691 (6.1) | |
|
| 2,725 (47.5) | 535 (9.3) | 2,100 (36.6) | 382 (6.7) | |
|
| |||||
|
| <0.001 | ||||
|
| 1,528 (55.4) | 300 (10.9) | 793 (28.8) | 136 (4.9) | |
|
| 4,950 (48.6) | 938 (9.2) | 3,615 (35.5) | 685 (6.7) | |
|
| 2,104 (52.0) | 378 (9.3) | 1,312 (32.4) | 252 (6.2) | |
|
| 0.017 | ||||
|
| 7,717 (50.9) | 1,449 (9.6) | 5,049 (33.3) | 954 (6.3) | |
|
| 865 (47.5) | 167 (9.2) | 671 (36.8) | 119 (6.5) | |
|
| |||||
|
| <0.001 | ||||
|
| 5,856 (50.6) | 1,033 (8.9) | 3,997 (34.5) | 693 (6.0) | |
|
| 2,726 (50.4) | 583 (10.8) | 1,723 (31.8) | 380 (7.0) | |
|
| <0.001 | ||||
|
| 6,234 (51.4) | 1,129 (9.3) | 4,007 (33.1) | 752 (6.2) | |
|
| 1,682 (50.1) | 377 (11.2) | 1,099 (32.7) | 201 (6.0) | |
|
| 496 (42.8) | 90 (7.8) | 481 (41.5) | 91 (7.9) | |
|
| 170 (48.3) | 20 (5.7) | 133 (37.8) | 29 (8.2) | |
|
| <0.001 | ||||
|
| 7,481 (51.6) | 1,395 (9.6) | 4,739 (32.7) | 871 (6.0) | |
|
| 845 (45.7) | 171 (9.2) | 692 (37.4) | 142 (7.7) | |
|
| 256 (39.1) | 50 (7.6) | 289 (44.1) | 60 (9.2) | |
|
| <0.001 | ||||
|
| 4,213 (52.7) | 821 (10.3) | 2,495 (31.2) | 465 (5.8) | |
|
| 3,296 (49.8) | 605 (9.1) | 2,282 (34.5) | 436 (6.6) | |
|
| 1,073 (45.1) | 190 (8.0) | 943 (39.7) | 172 (7.2) |
P<0.05 is significantly different.
Adjusted odds ratios and confidence intervals of probiotic supplement use.
| 0–6 mo user/Nonuser | 7–18 mo user/Nonuser | 0–18 mo user/Nonuser | |
| OR(95% CI) | OR(95% CI) | OR(95% CI) | |
|
| |||
|
| |||
|
| 1 | 1 | 1 |
|
| 1.00(0.90–1.11) | 1.23(1.15–1.32) | 1.26(1.11–1.44) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.13(0.99–1.28) | 1.19(1.10–1.29) | 1.17(1.00–1.36) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.03(0.88–1.20) | 2.58(2.27–2.94) | 2.46(1.91–3.16) |
|
| |||
|
| 1 | 1 | 1 |
|
| 0.90(0.79–1.04) | 1.22(1.11–1.33) | 1.11(0.94–1.31) |
|
| 0.83(0.71–0.98) | 1.22(1.10–1.34) | 1.17(0.98–1.41) |
|
| 0.81(0.66–0.99) | 1.18(1.04–1.34) | 0.92(0.73–1.18) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.26(1.09–1.45) | 1.00(0.91–1.10) | 1.23(1.03–1.46) |
|
| 1.08(0.94–1.23) | 1.18(1.08–1.29) | 1.13(0.96–1.34) |
|
| |||
|
| |||
|
| 1 | 1 | 1 |
|
| 1.01(0.91–1.13) | 1.12(1.05–1.21) | 1.07(0.94–1.22) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.07(0.95–1.20) | 1.09(1.01–1.17) | 1.06(0.92–1.22) |
|
| |||
|
| |||
|
| 1 | 1 | 1 |
|
| 0.96(0.83–1.11) | 1.26(1.14–1.39) | 1.44(1.18–1.75) |
|
| 0.89(0.75–1.05) | 1.12(1.00–1.26) | 1.31(1.04–1.64) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.05(0.88–1.25) | 1.14(1.02–1.28) | 1.08(0.88–1.33) |
|
| |||
|
| |||
|
| 1 | 1 | 1 |
|
| 1.20(1.07–1.34) | 0.91(0.84–0.98) | 1.17(1.02–1.34) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.21(1.06–1.38) | 1.01(0.92–1.10) | 0.96(0.81–1.13) |
|
| 1.01(0.80–1.27) | 1.31(1.15–1.50) | 1.34(1.06–1.70) |
|
| 0.64(0.40–1.02) | 1.00(0.79–1.27) | 1.17(0.78–1.75) |
|
| |||
|
| 1 | 1 | 1 |
|
| 1.08(0.91–1.29) | 1.34(1.20–1.49) | 1.48(1.22–1.79) |
|
| 1.04(0.77–1.42) | 1.84(1.54–2.20) | 2.05(1.53–2.75) |
|
| |||
|
| 1 | 1 | 1 |
|
| 0.94(0.84–1.06) | 1.18(1.09–1.27) | 1.20(1.04–1.38) |
|
| 0.91(0.77–1.09) | 1.53(1.38–1.70) | 1.48(1.22–1.78) |
Reference group.
P<0.05.
P<0.01.
P<0.001.
Predictors of probiotic supplement usage between 7 and 18 months.
| 0–18 mo user/0–6 mo user | ||
| OR | (95% CI) | |
|
| ||
|
| ||
|
| 1 | |
|
| 1.25 | (1.06–1.46) |
|
| ||
|
| 1 | |
|
| 1.03 | (0.86–1.25) |
|
| ||
|
| 1 | |
|
| 2.43 | (1.83–3.24) |
|
| ||
|
| 1 | |
|
| 1.20 | (0.98–1.48) |
|
| 1.41 | (1.12–1.77) |
|
| 1.11 | (0.82–1.50) |
|
| ||
|
| 1 | |
|
| 0.95 | (0.76–1.19) |
|
| 1.07 | (0.87–1.32) |
|
| ||
|
| ||
|
| 1 | |
|
| 1.04 | (0.88–1.22) |
|
| ||
|
| 1 | |
|
| 0.98 | (0.83–1.17) |
|
| ||
|
| ||
|
| 1 | |
|
| 1.49 | (1.18–1.88) |
|
| 1.45 | (1.10–1.90) |
|
| ||
|
| 1 | |
|
| 1.07 | (0.83–1.39) |
|
| ||
|
| ||
|
| 1 | |
|
| 0.96 | (0.81–1.14) |
|
| ||
|
| 1 | |
|
| 0.77 | (0.63–0.95) |
|
| 1.28 | (0.93–1.76) |
|
| 1.88 | (1.04–3.40) |
|
| ||
|
| 1 | |
|
| 1.36 | (1.06–1.74) |
|
| 2.02 | (1.36–3.02) |
|
| ||
|
| 1 | |
|
| 1.29 | (1.09–1.54) |
|
| 1.60 | (1.26–2.04) |
Reference group.
P<0.05.
P<0.01.
P<0.001.